Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, John Efthimiou, William Pullman, Hubert Schrezenmeier, Jens Panse

Blood (2024) 144 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2024-205866

Published: 2024

Journal Articles

The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate

Jeanette Walter, Benjamin Rolles, Yannic Schumacher, Frauke Theis, Leo Hansmann, Markus P. Radsak, Michael Heuser, Julia-Annabell Georgi, Jörg Chromik, Beatrice Drexler, Jörg Schubert, Kim Kricheldorf, Jens Panse, Thomas Stiehl, Tim H. H. Brummendorf, Bhavisha A. Patel, Neal S. Young, Emma M. Groarke, Fabian Beier

Blood (2024) 144 (Supplement 1): 4082.

https://doi.org/10.1182/blood-2024-207190

Published: 2024

Journal Articles

Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab

Phillip Scheinberg, Hazza Alzahrani, Alejandro Contento Gonzalo, Martin Höglund, Jin Seok Kim, Jens Panse, Melissa J Rose, Jörg Schubert, Yasutaka Ueda, Eng Soo Yap, Muriel Buri, Nicolo' Compagno, Brittany Gentile, Sasha Sreckovic, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2024-200889

Published: 2024

Journal Articles

Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates

David Dingli, Brian Mulherin, Peter Hillmen, Barbara Czech, Jens Panse

Blood (2024) 144 (Supplement 1): 5680.

https://doi.org/10.1182/blood-2024-203541

Published: 2024

Journal Articles

Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience

Gloria F. Gerber, Richard J. Kelly, Hisakazu Nishimori, Regina Horneff, Peter Hillmen, Uchendu O. Uchendu, Yiwei Zhang, Stacie Lallier, Jens Panse

Blood (2024) 144 (Supplement 1): 5698.

https://doi.org/10.1182/blood-2024-201443

Published: 2024

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Caroline Piatek, Jong Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Mohammed Mahdi, Peng Liu, Karl-Johan Myren, Andrew Messali, Flore Sicre de Fontbrune, Jens Panse, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2024-199506

Published: 2024

Journal Articles

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Phillip Scheinberg, Diego Villa Cle, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jörg Schubert, Kazutaka Sunami, Mustafa Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 1313.

https://doi.org/10.1182/blood-2024-200745

Published: 2024

Journal Articles

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Blood (2024) 144 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2024-204693

Published: 2024

Journal Articles

Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?

Elena E. Solomou, Alkmini Anastasiadi, Maria Papaioannou, Maria Angelopoulou, Panagiotis Zikos, Ioannis Assimakopoulos, Maria Dimou, Panagiotis Tsaftaridis, Jens Panse, Vasileios Tzounakas

Blood (2024) 144 (Supplement 1): 1317.

https://doi.org/10.1182/blood-2024-206170

Published: 2024

Journal Articles

Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Barbara Czech, Brianne Kerr, Sam Williamson, Jade Garratt-Wheeldon, Yasmin Taylor, Niall Hatchell, Christopher Patriquin

Blood (2024) 144 (Supplement 1): 5085.

https://doi.org/10.1182/blood-2024-209732

Published: 2024

Journal Articles

Quality of Life Analysis in Patients with AA Using the QLQ-AA/PNH-54 at Initial Diagnosis of AA - a Registry Based Analysis

Jeanette Walter, Andrea Petermann-Meyer, Hatice Soysal, Anna Doleschall, Deborah Christen, Kim Kricheldorf, Susanne Isfort, Tim H. Brümmendorf, Fabian Beier, Jens Panse

Blood (2023) 142 (Supplement 1): 5635.

https://doi.org/10.1182/blood-2023-182810

Published: 2023

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)

Jeanette Walter, Benjamin Rolles, Yannic Schumacher, Frauke Theis, Leo Hansmann, Daniel Heudobler, Markus Radsak, Michael Heuser, Julia-Annabell Georgi, Jörg Chromik, Beatrice Drexler, Jörg Schubert, Kim Kricheldorf, Susanne Isfort, Jens Panse, Tim H. Brümmendorf, Fabian Beier

Blood (2023) 142 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2023-183075

Published: 2023

Journal Articles

Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter

Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, Frauke Theis, Jens Panse, Tim H. Brümmendorf, Fabian Beier

Blood (2023) 142 (Supplement 1): 5636.

https://doi.org/10.1182/blood-2023-183046

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials

Jens Panse, Jaroslav Cermak, Olena Kyselova, Akihiko Gotoh, Fahri Sahin, Hubert Schrezenmeier, Alice C. Chang, Brittany Gentile, Marianne Uguen, Bing Han

Blood (2023) 142 (Supplement 1): 4090.

https://doi.org/10.1182/blood-2023-177584

Published: 2023

Journal Articles

OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients

Oksana Karnabeda, Valentyn Moskalenko, Zoreslava Lysak, Narinder Nangia, Charlotte A. Osborne, J. Steve Whitaker, Eleni Gavriilaki, Jens Panse

Blood (2023) 142 (Supplement 1): 573.

https://doi.org/10.1182/blood-2023-177921

Published: 2023

Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2023-190015

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Blood (2023) 142 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2023-178304

Published: 2023

NARROW

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate

Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab

Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates

Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment

Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?

Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

Quality of Life Analysis in Patients with AA Using the QLQ-AA/PNH-54 at Initial Diagnosis of AA - a Registry Based Analysis

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)

Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials

OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only